Particle3D
Particle3D (operating as Ossiform ApS) is a Danish biomedical company developing 3D-printed β-tricalcium phosphate bone substitutes and preclinical research scaffolds for orthopedic reconstruction and bone/cancer research applications, currently in preclinical/regulatory stage without approved clinical products.
- Company typePrivate
- Founded2017
- HeadquartersOdense, Denmark
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Particle3D does
Particle3D, legally Ossiform ApS (CVR 38838512), is a Danish biomedical company founded in 2017 and headquartered at Oslogade 1, 5000 Odense C, Denmark. It develops 3D-printed bone substitutes based on β-tricalcium phosphate (β-TCP), a resorbable bioceramic that the company shapes via proprietary 3D printing techniques to produce indication-specific, patient-tailored implants. The dual-product portfolio consists of Ossiform Bone — a bio-integrative, structural orthopedic bone graft substitute for clinical reconstruction procedures (orthopedic and spine applications) — and the Ossiform Research Line, which includes P3D Scaffolds and Cell Culture Plates sold to academic and industry researchers in bone tissue engineering and cancer research. The company operates with a small team of 1–10 employees and holds ISO 13485 certification issued by BSI; its clinical products are not yet cleared by regulatory authorities and are not approved for sale, while the technology has been tested in preclinical studies only.
Particle3D firmographics
Firmographics- Name
- Particle3D
- Legal name
- Ossiform ApS
- Website
- https://particle3d.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Particle3D (operating as Ossiform ApS) is a Danish biomedical company developing 3D-printed β-tricalcium phosphate bone substitutes and preclinical research scaffolds for orthopedic reconstruction and bone/cancer research applications, currently in preclinical/regulatory stage without approved clinical products.
- Ownership category
- akta.pro rank
Particle3D industry classification
Industry- Product category
- Orthopedic Bone Graft Substitutes
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)
- akta.pro secondary industries
- Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH), Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB), Medical & Dental Prototyping (Models, Guides, Pre-Op Planning) (IMAAAFAI)
Keywords
Where Particle3D is headquartered
LocationHeadquarters
- HQ city
- Odense
- HQ country
- Denmark
- HQ region
- Europe
Offices1 record
Markets served
Particle3D business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Ossiform Bone Products: Sale of 3D printed β-TCP bone substitute products for clinical use in bone reconstruction procedures. Currently in preclinical/regulatory approval stage with products not yet cleared for sale.
- P3D Scaffolds and Research Products: Sale of P3D Scaffolds and cell culture plates for bone and cancer research applications in preclinical settings
- Professional Services/Collaboration: Close collaboration with physicians and industry partners suggests potential for research collaborations and development services
Go-to-market motion3 records
Distribution channels3 records
Marketing channels5 records
Particle3D product offering
Product offeringCore offering
Particle3D (operating as Ossiform) develops and manufactures 3D-printed bioceramic bone substitutes made from β-tricalcium phosphate (β-TCP). Its commercial offerings include Ossiform Bone, a structural bio-integrative bone graft substitute intended for orthopedic and spine reconstruction, and the Ossiform Research Line comprising P3D Scaffolds and Cell Culture Plates for preclinical bone and cancer research. Clinical products are currently in preclinical / regulatory review and are not yet cleared for sale; research products are sold directly to academic and industry researchers.
Product overview
Ossiform offers a dual-product portfolio centered on 3D printed bone replacement technology. The core commercial offering is Ossiform Bone, which provides bio-integrative and structural orthopedic bone graft substitutes made from 3D printed β-tricalcium phosphate for clinical applications. Complementing this is the Ossiform Research Line, which includes P3D Scaffolds and Cell Culture Plates as specialized research products for bone and cancer studies in preclinical settings. Both product lines utilize the company's proprietary 3D printing technique to create resorbable ceramic bone substitutes.
Differentiator
Problem solved
Functional benefit
Brands
- Ossiform Bone: Bio-integrative and structural orthopedic bone substitutes made from 3D printed β-tricalcium phosphate.
- Ossiform Research Line
- P3D Scaffolds
- We Print Bone
Products and services
- Ossiform Bone Bio-integrative and structural orthopedic bone graft substitute solutions made from 3D printed β-tricalcium phosphate (β-TCP), a resorbable material designed to support bone regeneration with indication-specific biomechanical considerations. Intended for orthopedic and spine surgeons performing bone reconstruction procedures in hospitals and surgical centers.
- Ossiform Research Line A research product line providing natural bone-like environments for bone tissue engineering in preclinical research, enabling disease mechanism studies and new treatment testing. Served to academic researchers, institutions, and biotech / pharma R&D teams studying bone and cancer.
- P3D Scaffolds 3D printed bioceramic scaffolds made from β-tricalcium phosphate, designed for bone and cancer research applications in preclinical studies. Sold to academic and industry researchers via the company's website.
- Cell Culture Plates Part of the Ossiform Research Line, providing a 3D printed cell culture system for enhancing bone and cancer research. Sold to academic and industry researchers for preclinical experimentation.
Quantifiable outcome
- Potential to reduce need for permanent implant solutions
- +2 more outcomes
Companies that use Particle3D
Customer profileSegments2 records
Ideal customer profiles2 records
Particle3D technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Particle3D partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and minor.
- Imbros Pty LtdcoreOssiform announced a new distribution partnership with Imbros Pty Ltd covering specified regions. This partnership expands Ossiform's distribution reach for their bone substitute products and P3D Scaffolds through Imbros' established regional distribution network.
- ABHI 2026 U.S. Accelerator ProgramminorOssiform was selected for the ABHI 2026 U.S. Accelerator Program, a respected program designed to support medtech companies in entering and expanding in the U.S. market. This accelerator program provides mentorship, networking, and market access support.
Scale indicators3 records
Recent moves6 records
Expansion highlights6 records
Particle3D competitors and assessment
Company assessmentDirect peers
- Cerapedics: Cerapedics markets i-FACTOR, a small peptide (P-15) bone graft for spine and orthopedic fusion. It is comparable as a bone graft substitute company serving the same orthopedic/spine surgeon segment with a biologic alternative to autograft.
- Xtant Medical: Xtant Medical develops and markets orthobiologic products including bone grafts and spine fixation for orthopedic and neurosurgical applications. It is comparable as a focused bone graft and orthobiologics peer serving clinicians with structural bone replacement solutions.
- Biogennix: Biogennix develops and commercializes synthetic bone graft substitutes including calcium phosphate-based bone void fillers for orthopedic and spine fusion. It is directly comparable to Particle3D as a competitor in synthetic, resorbable bone graft substitutes targeting the same clinician customer base.
Emerging players
- Organovo: Organovo is a bioprinting and tissue engineering company developing 3D-printed human tissue for therapeutic and research applications. It is comparable as a peer using 3D bioprinting approaches to create human tissue constructs, including preclinical disease modeling similar to Particle3D's research line.
- Cellink (BICO Group): Cellink/BICO provides bioprinting hardware, bioinks, and tissue engineering workflows used by researchers building 3D tissue constructs, including bone. It is comparable as a 3D bioprinting platform vendor whose technology stack enables similar research applications as Particle3D's P3D Scaffolds line.
- Curasan AG: Curasan AG develops, manufactures, and markets synthetic bone regeneration materials for dental, orthopedic, and trauma applications. It is comparable as a European-focused peer in synthetic bone graft substitutes with overlapping indication sets in dental and orthopedic bone repair.
Broad incumbents
- Smith+Nephew: Smith+Nephew is a global medical device company with an orthopedics and sports medicine portfolio, including bone graft substitutes and regenerative products for joint reconstruction. It is comparable as a broad incumbent operating in orthopedic reconstruction, the same downstream surgical category that Particle3D targets.
- Integra LifeSciences: Integra LifeSciences manufactures and markets regenerative tissue technologies and orthopedic implants including bone graft substitutes (e.g., Integra Dermal Regeneration Template and OrthoPediatrics adjacencies). It is comparable as a broad incumbent with overlapping bone graft and orthopedic product lines targeting similar surgical customers.
- Stryker: Stryker is a global medical device leader with a large orthopedics and spine franchise including bone substitutes, regenerative materials, and trauma implants. It is comparable as a broad incumbent in the orthopedic and bone graft space with hospital sales reach that could compete or partner with Particle3D.
- Baxter International (BioSurgery / bone graft portfolio): Baxter offers a broad surgical and biosurgery portfolio including bone graft substitutes and regenerative medicine products through Tisseel, Floseal, and other biologics. It is comparable as a large incumbent offering bone graft and related surgical regenerative solutions across hospitals worldwide.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Particle3D social profiles
Digital presenceParticle3D compliance and trust
Trust signalCompliance1 record
Particle3D financial estimates
Financial estimateRevenue estimate
Valuation estimate
Particle3D leadership team
Management profileNumber of profiles
Profiles6 records
Particle3D funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Particle3D M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Particle3D
What does Particle3D do?
Particle3D (operating as Ossiform) develops and manufactures 3D-printed bioceramic bone substitutes made from β-tricalcium phosphate (β-TCP). Its commercial offerings include Ossiform Bone, a structural bio-integrative bone graft substitute intended for orthopedic and spine reconstruction, and the Ossiform Research Line comprising P3D Scaffolds and Cell Culture Plates for preclinical bone and cancer research. Clinical products are currently in preclinical / regulatory review and are not yet cleared for sale; research products are sold directly to academic and industry researchers.
Is Particle3D a public or private company?
Particle3D is a private company. It is classified as venture growth investor backed and is currently operating.
When was Particle3D founded?
Particle3D was founded in 2017. It employs 1 to 10 people.
Where is Particle3D based?
Particle3D is headquartered in Odense, Denmark, in the Europe region.
How does Particle3D make money?
Three revenue lines are on record. Ossiform Bone Products are the primary driver. The others are P3D Scaffolds and Research Products and professional Services/Collaboration.
Who are Particle3D's main competitors?
Direct peers on record are Cerapedics, Xtant Medical and Biogennix. Emerging players are Organovo, Cellink (BICO Group) and Curasan AG. Broad incumbents are Smith+Nephew, Integra LifeSciences, Stryker and Baxter International (BioSurgery / bone graft portfolio).
Does Particle3D have an API?
No public API is recorded for Particle3D.
What industry is Particle3D in?
Particle3D's product category is Orthopedic Bone Graft Substitutes. Its primary akta.pro industry code is HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM), with a secondary code of HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration. Its NAICS code is 541714 and its SIC code is 3842.